{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=41",
    "query": {
      "condition": "Genetics/Birth Defects",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 8007,
    "total_pages": 801,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetics%2FBirth+Defects&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T23:35:46.086Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01018056",
      "title": "Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "D-serine",
          "type": "DRUG"
        },
        {
          "name": "Riluzole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2009-11",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-30",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01018056"
    },
    {
      "nct_id": "NCT06188741",
      "title": "Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 1",
        "Plexiform Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "1 Year to 8 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-08-27",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06188741"
    },
    {
      "nct_id": "NCT00046202",
      "title": "Study of Inborn Errors of Cholesterol Synthesis and Related Disorders",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lysosomal Storage Disease",
        "Cholesterol Metabolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Day to 99 Years"
      },
      "enrollment_count": 344,
      "start_date": "2002-10-09",
      "completion_date": "2023-11-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046202"
    },
    {
      "nct_id": "NCT05630066",
      "title": "A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angelman Syndrome"
      ],
      "interventions": [
        {
          "name": "Alogabat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-07-27",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Carrboro",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05630066"
    },
    {
      "nct_id": "NCT05422222",
      "title": "Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-121/TEZ/D-IVA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 210,
      "start_date": "2022-06-21",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 19,
      "location_summary": "Orange, California • Palo Alto, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422222"
    },
    {
      "nct_id": "NCT01782027",
      "title": "Mendelian Reverse Cholesterol Transport Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cholesterol, HDL",
        "Lipid Metabolism, Inborn Errors",
        "Tangier Disease",
        "LCAT Deficiency",
        "Cholesteryl Ester Transfer Protein (CETP) Deficiency"
      ],
      "interventions": [
        {
          "name": "3H-cholesterol bound to albumin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2012-10",
      "completion_date": "2024-09-04",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01782027"
    },
    {
      "nct_id": "NCT00031005",
      "title": "Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukocyte-Adhesion Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "modified stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2002-02",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031005"
    },
    {
      "nct_id": "NCT05533866",
      "title": "Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "APR-TD011",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-02-06",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533866"
    },
    {
      "nct_id": "NCT01172301",
      "title": "Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Essential amino acid intake + Leucine vs total AA supplement",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 14,
      "start_date": "2008-07",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2015-08-11",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172301"
    },
    {
      "nct_id": "NCT04690322",
      "title": "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Factor VIII"
      ],
      "interventions": [
        {
          "name": "Eloctate",
          "type": "DRUG"
        },
        {
          "name": "Adynovate",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-04-15",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-23T23:35:46.086Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04690322"
    }
  ]
}